Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cascadian Therapeutics, Inc.

http://www.cascadianrx.com/

Latest From Cascadian Therapeutics, Inc.

Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs

Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.

Deals Cancer

Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO

Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

Deals Business Strategies

Ocugen Eyes Broad Retinitis Pigmentosa Indication With One Gene Therapy

Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.

StartUps and SMEs Gene Therapy

New RWE Framework Aims To Get IVDs To Market Faster, Surveil COVID-19 Tests

Three years after the US FDA released a guidance to use real-world evidence in premarket applications, the stakeholder group MDIC has unveiled a framework for how IVD RWE can be captured and used by sponsors for premarket applications.

Regulation Research & Development
See All

Company Information

  • Other Names / Subsidiaries
    • Alpine Biosciences
    • Biomira
    • Oncothyreon, Inc.
    • Seattle Genetics, Inc.s
UsernamePublicRestriction

Register